Antibiotic resistance is often framed as a prescribing problem: use fewer drugs and use them correctly. That is necessary, but a clinician facing a sick patient without timely microbiology may have to treat broadly before the pathogen and susceptibility are known. Patients without affordable access may buy incomplete or inappropriate treatment.
WHO’s 2025–35 strategic and operational priorities combine infection prevention, universal access to quality diagnosis and appropriate treatment, strategic information, governance and finance. The combination matters because stewardship without diagnostic capacity can become delay rather than precision.
The sample-to-answer chain
A test requires correct sampling, transport, laboratory quality, interpretation and delivery of the result while it can change care. Counting machines does not measure this chain.
Turnaround time is clinical
A result after discharge may help surveillance but not the patient. Hospitals need systems to review pending cultures and narrow, stop or change treatment.
Access beyond major hospitals
Rural and low-resource facilities need referral networks, transport and minimum diagnostics. Point-of-care tests can help when performance, training and quality assurance are appropriate.
Affordability shapes behaviour
If consultation and testing cost more than empirical antibiotics, patients receive a financial signal to skip diagnosis. Coverage policy should align with stewardship goals.
Prevention reduces diagnostic pressure
Clean water, vaccination, infection control and safe care prevent infections and reduce demand. Stewardship budgets should not compete with the infrastructure that makes prescribing less necessary.
Surveillance needs representative data
Laboratory data can overrepresent severe urban cases. Countries should report coverage and sampling bias, connect human, animal and environmental evidence carefully, and protect privacy.
Do not punish clinicians for uncertainty
Guidelines, infectious-disease advice and rapid review support better decisions. Crude prescription quotas may deter justified treatment or encourage gaming.
A people-centred measure
Track time to appropriate therapy, patient cost, severe outcomes, access disparities and medicine quality alongside total consumption.
Resistance emerges biologically but is amplified by systems. A patient should not have to choose between an unaffordable test and a blind treatment. Diagnostics are part of equitable access, not a laboratory luxury.
